The first activating mutations of MET were identified in hereditary papillary renal carcinoma (HPRC), and the authors suggested that the mutations affecting the kinase domain of MET (M1149T, V1206L, V1238I, D1246N, and Y1248C) were causal in HPRC [121]. Here, MET is linked to hereditary papillary renal cell carcinoma.